Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276632 | 0.93 | CYP11B1 (0.37) | NPC1TTRKMT2A | |
| SCHEMBL6748112 | 0.79 | NPC1 (0.51) | NPC1TTRKMT2A | |
| SCHEMBL6743887 | 0.79 | NPC1 (0.66) | NPC1TTRKMT2A | |
| SCHEMBL6746228 | 0.72 | MAP2K1 (0.53) | KMT2A | |
| SCHEMBL6746195 | 0.71 | HTR1A (0.50) | — | |
| SCHEMBL6748805 | 0.71 | NPC1 (0.55) | NPC1TTRMAPTLMNA | |
| SCHEMBL1762389 | 0.70 | MAP2K1 (0.35) | KMT2A | |
| SCHEMBL6452066 | 0.65 | HDAC1 (0.43) | KMT2A | |
| SCHEMBL6746387 | 0.64 | MAP2K1 (0.56) | KMT2A | |
| SCHEMBL1762381 | 0.61 | CYP11B2 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | NPC1 2509/4885TTR 4604/4885KMT2A 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.